Drug Profile
Research programme: antibody-based cancer therapeutics - Menarini/Oxford BioTherapeutics
Alternative Names: OX-002Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Oxford BioTherapeutics
- Developer Menarini; Oxford BioTherapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
- Mechanism of Action DEC-205 receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer